MARKET

KNSA

KNSA

Kiniksa Pharmaceuticals International, plc
NASDAQ
41.67
+0.68
+1.66%
After Hours: 41.67 0 0.00% 16:10 12/05 EST
OPEN
41.12
PREV CLOSE
40.99
HIGH
42.00
LOW
40.31
VOLUME
339.54K
TURNOVER
--
52 WEEK HIGH
42.98
52 WEEK LOW
17.82
MARKET CAP
3.16B
P/E (TTM)
92.95
1D
5D
1M
3M
1Y
5Y
1D
Kiniksa COO Eben Tessari Reports Disposal of Common Shares
Reuters · 4d ago
Weekly Report: what happened at KNSA last week (1124-1128)?
Weekly Report · 4d ago
Weekly Report: what happened at KNSA last week (1117-1121)?
Weekly Report · 11/24 09:40
How Investors Are Reacting To Kiniksa Pharmaceuticals (KNSA) Raised Outlook Following Strong Arcalyst Sales
Simply Wall St · 11/23 22:16
A Look at Kiniksa Pharmaceuticals (KNSA) Valuation Following Raised Guidance on Strong Q3 Earnings
Simply Wall St · 11/20 15:21
Kiniksa Pharmaceuticals (KNSA) Receives a Buy from Jefferies
TipRanks · 11/18 14:26
Weekly Report: what happened at KNSA last week (1110-1114)?
Weekly Report · 11/17 09:41
Exploring High Growth Tech Stocks in the US Market
Simply Wall St · 11/14 11:08
More
About KNSA
Kiniksa Pharmaceuticals International, plc is a biopharmaceutical company focused on discovering, acquiring, developing and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications. Its portfolio of assets is based on strong biologic rationale or validated mechanisms and offers the potential for differentiation. Its ARCALYST is used for the treatment of recurrent pericarditis and reduces the risk of recurrence in adults and children 12 years and older. ARCALYST is also approved for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome, and the maintenance of remission in Deficiency of Interleukin-1 Receptor Antagonist. Its other portfolio includes KPL-387, KPL-1161, Abiprubart, and Mavrilimumab. Mavrilimumab is an investigational monoclonal antibody inhibitor targeting granulocyte-macrophage colony stimulating factor receptor alpha.

Webull offers Kiniksa Pharmaceuticals Internationl PLC stock information, including NASDAQ: KNSA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KNSA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading KNSA stock methods without spending real money on the virtual paper trading platform.